Alpha Teknova (NASDAQ:TKNO) Posts Earnings Results, Beats Estimates By $0.01 EPS

Alpha Teknova (NASDAQ:TKNO) posted its quarterly earnings data on Wednesday. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01, FiscalAI reports. Alpha Teknova had a negative net margin of 38.37% and a negative return on equity of 24.94%. The firm had revenue of $12.70 million for the quarter, compared to analysts’ expectations of $11.71 million.

Here are the key takeaways from Alpha Teknova’s conference call:

• Teknova posted a second consecutive quarterly revenue record, up 22% year over year. Growth was led by custom products for life science tools and diagnostics customers, with an encouraging but still early uptick in biopharma demand; Clinical Solutions revenue rose 86% from a small, lumpy base.
• New offerings are showing early traction: Build-Tek has generated quote requests from more than 100 organizations, while over 60% of Fill-Tek orders quoted so far are for GMP-grade products. Management sees these tools as ways to attract custom demand and deepen customer relationships, though Fill-Tek’s larger revenue contribution may take years to develop.
• Gross margin increased to 38.0% from 30.7%, and the net loss narrowed to $3.5 million from $4.3 million year over year. Adjusted EBITDA loss and free cash outflow also improved, although the company remains unprofitable.
• Teknova raised its 2026 revenue guidance to $46 million–$48 million and expects full-year free cash outflow below $8 million. Management said a positive Adjusted EBITDA quarter could come before the end of 2027 if markets strengthen and commercial investments deliver, while forecasting at least $8 million of operating expenses in Q4.
• The recovery remains uneven: small and mid-sized biotech discovery spending, including catalog demand, is still soft, and management said it wants to see the funding-driven improvement continue for another few quarters. The company also completed a $46 million equity raise, which strengthens its balance sheet but expands its share count.

Alpha Teknova Stock Down 1.3%

NASDAQ:TKNO opened at $7.27 on Thursday. The firm has a 50-day simple moving average of $7.70 and a two-hundred day simple moving average of $4.94. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.48 and a current ratio of 4.49. Alpha Teknova has a fifty-two week low of $1.91 and a fifty-two week high of $9.48. The firm has a market cap of $390.51 million, a P/E ratio of -23.69 and a beta of 0.96.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on TKNO shares. TD Cowen boosted their price objective on Alpha Teknova from $7.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Jefferies Financial Group began coverage on Alpha Teknova in a research report on Thursday, September 17th. They issued a “buy” rating and a $9.00 price objective on the stock. Roth Capital started coverage on Alpha Teknova in a report on Wednesday, August 5th. They set a “buy” rating and a $7.00 target price for the company. Zacks Research raised Alpha Teknova to a “hold” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings cut shares of Alpha Teknova from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Alpha Teknova has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Alpha Teknova Company Profile

Alpha Teknova, Inc is a life sciences company that develops and manufactures critical reagents and other products used in biomedical research, biopharmaceutical development and advanced therapies. The company provides laboratory and production materials designed to support applications including cell and gene therapy, molecular diagnostics, next-generation sequencing, vaccine development and pharmaceutical manufacturing.

Its offerings include research-use-only and current Good Manufacturing Practice (cGMP) reagents, buffers, media and other custom-formulated solutions.